A compound can reduce methamphetamine-related behavior in animals and still fail as a drug-development candidate. GZ-793A illustrates that distinction. A 2012 rat study reported favorable effects on methamphetamine self-administration and conditioned preference. A later mechanistic study identified cardiac ion-channel effects and stated that development would not be pursued.
Reading the later evidence alongside the earlier results prevents a historical “promising treatment” description from becoming an unsupported clinical recommendation.
What was GZ-793A designed to do?
GZ-793A was a lobelane-related experimental compound targeting vesicular monoamine transporter-2, or VMAT2. The research program sought to reduce dopamine availability for methamphetamine-induced release and thereby alter methamphetamine’s reinforcing effects.
The studies concern this particular compound. They do not establish that every VMAT2 inhibitor shares its behavioral effects or cardiac liabilities.
What did the early rat experiments find?
Beckmann and colleagues used adult male Sprague-Dawley rats. Animals self-administered intravenous d-methamphetamine hydrochloride at 0.03 mg/kg per infusion under a fixed-ratio-five schedule. GZ-793A was given subcutaneously 20 minutes before sessions, with doses expressed as salt weights.
Acute GZ-793A doses of 10, 15 and 30 mg/kg reduced methamphetamine infusions. In a separate cocaine group, only 30 mg/kg significantly reduced cocaine infusions. Acute food-maintained responding was not significantly reduced under the tested conditions.
Repeated GZ-793A at 15 mg/kg continued to reduce methamphetamine self-administration across seven daily sessions, with four rats per treatment group. The investigators did not observe tolerance over that interval. In a separate food experiment, six rats per group showed increased pellet earning during later repeated-treatment sessions.
Those control results argue against simple generalized response suppression at the selected dose. They are not a comprehensive assessment of toxicity or long-term safety.
Was the compound itself reinforcing?
When intravenous GZ-793A at 0.01–0.3 mg/kg per infusion replaced methamphetamine, responding did not differ from saline substitution. That experiment used seven rats per group.
In a separate conditioned-place-preference experiment, also with seven animals per group, GZ-793A pretreatment at 15 mg/kg subcutaneously blocked preference associated with 0.5 mg/kg subcutaneous methamphetamine. GZ-793A alone produced neither demonstrated preference nor aversion under that protocol.
Self-administration and place preference are different behavioral assays. Their negative results for GZ-793A suggested low reinforcing potential under those conditions, but did not prove absence of human abuse liability.
What did the later neurochemical study add?
Nickell and colleagues examined isolated rat striatal slices. Methamphetamine at 5 micromolar evoked dopamine release; GZ-793A at selected concentrations reduced that release. The principal methamphetamine-release experiment used tissue from seven rats.
GZ-793A alone did not significantly increase basal dopamine release. It also did not significantly inhibit nicotine-evoked release in the five-rat experiment or electrically stimulated release in experiments involving five to six rats per concentration. These findings supported selectivity among the tested release conditions.
The concentrations were laboratory bath concentrations, not measured human blood levels or doses that can be prescribed. Mechanistic selectivity in brain tissue does not establish selectivity across all organs.
Which cardiac findings changed the development decision?
The later study tested the human ether-a-go-go-related gene channel, commonly called hERG, in engineered human embryonic kidney cells. GZ-793A inhibited radioligand binding with an IC50 of 0.81 ± 0.11 micromolar and inhibited channel current with an IC50 of approximately 0.07 micromolar. The current experiment reported n=3; the binding experiments used several independent cell preparations.
These are two different assays. Binding inhibition and reduced electrical current should not be treated as interchangeable measurements, even though they supported the same concern.
In isolated rabbit cardiac Purkinje fibers, GZ-793A at 0.03–0.3 micromolar prolonged action-potential duration. Other parameters, including resting membrane potential, action-potential amplitude and maximum depolarization rate, were not significantly altered. The published table did not provide an animal denominator for that preparation, so no rabbit sample size is inferred here.
The findings indicated potential proarrhythmic liability, not a measured incidence of arrhythmia in human patients. These cardiac effects belonged to GZ-793A testing; they were not a newly measured methamphetamine effect.
Why did favorable behavioral results not settle safety?
The early experiments addressed reinforcement, conditioned preference and selected control behaviors. They did not test the later-identified cardiac channel effects. The 2017 paper explicitly stated that GZ-793A would not be pursued as a methamphetamine-use-disorder pharmacotherapy because of those liabilities.
That was the investigators’ historical development decision. It does not establish the current status of every related compound, and no human efficacy or safety trial of GZ-793A was reported in these two papers.
The broader evidentiary lesson is that benefit, mechanism and safety require different measurements. Reduced drug seeking, lack of preference for a candidate compound and absence of weight loss cannot substitute for targeted cardiac assessment.
Scientific sources
Beckmann JS, Denehy ED, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology. 2012;220(2):395–403. doi:10.1007/s00213-011-2488-9. Full-text author manuscript.
Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. European Journal of Pharmacology. 2017;795:143–149. doi:10.1016/j.ejphar.2016.12.016. Full-text author manuscript. Historical original animal, tissue and cell studies.
Leave a Reply